Cytogens vs Cytomaxes: The Two Khavinson Bioregulator Classes Explained

Cytogens and Cytomaxes are the two classes of Khavinson peptide bioregulators. Cytogens are short synthetic peptides (typically 2-4 amino acids) designed to mimic the active fragment of a natural regulator. Cytomaxes are natural polypeptide complexes extracted from the organs of young animals. Both share the same organ-targeted bioregulation hypothesis but differ in origin and composition.

TL;DR: The Khavinson family splits by where the peptide comes from. Cytomaxes (e.g., thymalin, cortexin, retinalamin) are extracted from young-animal organs and are mostly injectable. Cytogens (e.g., vilon, crystagen, livagen, vesugen, and the longevity peptide epithalon) are lab-synthesized short peptides, often available orally. The same organ is frequently targeted by a Cytomax and a Cytogen sibling. The human evidence is thin outside epithalon and thymalin, and most of it is Russian-language. Not FDA-approved; research use only.

Research-use and educational content only. This page is not medical advice. These compounds are not approved by the FDA for human use and are sold for research purposes only. VialBase publishes independent education and may earn an affiliate commission from vendor links on this page; see the disclosure under “Where to Buy.” Consult a qualified healthcare professional before making any health decisions.

At a Glance

Note on the table: VialBase classifies each compound from its vault profile. svetinorm, glandokort, and ventfort are described in the source notes as organ-extract bioregulators yet are dosed orally/SubQ at “10-20 mg per cycle” like the synthetic Cytogens, so their Cytogen-vs-Cytomax registration is not perfectly clean. Evidence note: as of this writing, Svetinorm, Glandokort, and Ventfort return zero PubMed-indexed records — their composition (organ-extract complex vs. defined synthetic peptide) is documented only in manufacturer/vendor literature (the St. Petersburg Institute / Cytomax-Cytogen product lines), not in any peer-reviewed source we could locate. Treat their classification here as vendor-reported, not independently verified.

The Khavinson Bioregulation Hypothesis

Both classes trace to the work of Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology, which has studied short peptides as tissue-specific regulators for several decades. Khavinson termed these compounds peptide bioregulators: very short peptide sequences administered in brief, intensive courses — typically 10-20 days — whose effects are reported to persist after the course ends. That persistence is attributed to epigenetic modulation: the hypothesis that a short peptide can interact with cellular machinery (chromatin, gene expression) to nudge a specific tissue back toward a more youthful or balanced pattern.

This is the unifying claim across the entire family. For a Cytomax, you deliver a natural mixture of organ peptides; for a Cytogen, you deliver a single synthetic fragment meant to carry the same signal. Either way, the proposed mechanism is the same: organ-targeted bioregulation rather than a classic receptor-agonist drug effect.

Honest framing. The core mechanism — direct, sequence-specific peptide-DNA interaction driving gene expression — remains scientifically controversial and is not established to Western pharmacological standards. The great majority of supporting literature is Russian-language, study designs frequently fall below FDA-grade rigor (small samples, limited blinding, longitudinal confounding), and almost none of these compounds has an FDA-registered clinical trial. The historical track record inside Russian bioregulatory medicine is real and long, but it is not a substitute for the controlled trials that would validate the class in the West. Treat the bioregulation hypothesis as a plausible, regionally-supported model — not as proven biology.

What Are Cytomaxes?

Cytomaxes are the original form of Khavinson bioregulator: natural polypeptide complexes purified from the organs of young animals. Because they are extracts, a Cytomax is not a single molecule with one sequence — it is a tissue-derived mixture of peptides. The logic is that a young organ contains the regulatory peptide signals that aging tissue has lost, and reintroducing them helps normalize the target organ’s function. Several Cytomaxes are registered drugs in Russia and are administered clinically by injection.

The Cytomax roster (organ target → what the vault reports):

• thymalin — thymus. A thymus peptide complex that restores thymic function, supports immune-cell (T-cell) education, and modulates immune overactivation. Described as one of the oldest bioregulators with a strong safety record; commonly used in elderly patients for immune revitalization and a fixture in immune/cancer-support stacks. Dosed ~10 mg/day for 5-10 days, SubQ.
• cortexin — brain cortex. A peptide complex extracted from calf/porcine cortex acting as a neurotrophic factor — supports synaptic plasticity, antioxidant defense, and cerebral blood flow; used for neuroprotection, stroke recovery, and cognitive rehabilitation. Functionally compared to cerebrolysin but with different extraction and composition.
• retinalamin — retina. A retinal bioregulator extract used ophthalmically; administered by injection in clinical settings (parabulbar or IM). Systemic impact is minimal because the effect is localized to ocular tissue.
• svetinorm — liver. A hepatoprotective bioregulator used in Russian clinical practice for fatty liver, alcohol damage, and hepatitis recovery; described as working at the epigenetic level to normalize liver-tissue gene expression. (Dosed orally/SubQ at 10-20 mg per cycle — see the table note on its classification.)
• glandokort — adrenal cortex. An adrenal bioregulator that aims to normalize cortisol rhythms and improve adrenal resilience and energy in chronic-fatigue/burnout states.
• ventfort — vascular endothelium. A vascular bioregulator that supports endothelial repair, microcirculation, and vessel elasticity, and aims to reduce age-related vascular stiffness — functionally the organ-extract counterpart to the synthetic vesugen.

What Are Cytogens?

Cytogens are the synthetic answer to the Cytomaxes: instead of extracting a peptide mixture from an organ, chemists synthesize a short defined peptide (commonly a di-, tri-, or tetrapeptide) intended to reproduce the active fragment of the natural regulator. Two practical consequences follow. First, a Cytogen has a known, reproducible sequence — easier to manufacture, standardize, and quality-test by HPLC. Second, several Cytogens are described as orally available, which is a meaningful convenience advantage over injection-only Cytomaxes.

The Cytogen roster (organ target → what the vault reports):

• vilon — thymus / immune. A short thymic peptide (described as a dipeptide, Lys-Glu — among the shortest known bioactive peptides) thought to regulate aging- and immune-related gene expression, enhance chromatin structure and DNA repair, and restore thymic function and T-cell counts in aging populations. Oral, sublingual, or SubQ.
• crystagen — thymus. A thymus bioregulator (described as a tripeptide) reported to support immune balance by modulating thymic gene expression; profile is anti-inflammatory, regenerative, and immunoprotective. Oral or SubQ.
• livagen — liver. A hepatoprotective bioregulator supporting liver-cell regeneration and enzyme expression, with epigenetic modulation of hepatic gene expression; the synthetic counterpart to the liver Cytomax svetinorm. Oral or SubQ.
• vesugen — vascular endothelium. A vascular bioregulator supporting endothelial repair, vessel elasticity, and microcirculation, operating epigenetically to maintain vascular gene expression; the synthetic counterpart to the vascular Cytomax ventfort. Oral or SubQ.
• epithalon — pineal / telomere. A synthetic tetrapeptide (Ala-Glu-Asp-Gly, ~390 Da) developed as the synthetic version of epithalamin, the natural pineal Cytomax. Its signature mechanism is activation of telomerase (hTERT) leading to telomere elongation, alongside pineal/melatonin regulation and antioxidant activity. It is the most-researched compound in the entire family and is usually treated as a standalone longevity peptide. Subcutaneous (IV also reported).

The epithalon / epithalamin pair is the cleanest illustration of the whole taxonomy: epithalamin is the natural pineal extract (Cytomax-type), and epithalon is the lab-made tetrapeptide built to carry the same signal (Cytogen-type).

Key Differences

• Origin is the dividing line. Cytomax = extracted from a young animal organ. Cytogen = synthesized in a lab. Everything else flows from that.
• Composition. Cytomaxes are complexes — multi-peptide tissue mixtures with no single defined sequence. Cytogens are single short peptides with a known sequence (e.g., Lys-Glu for vilon, Ala-Glu-Asp-Gly for epithalon).
• Route. Classic Cytomaxes (thymalin, cortexin, retinalamin) are injection-first and used clinically by injection. Cytogens emphasize oral availability as a convenience advantage, though SubQ is also used.
• Standardization and testing. A defined synthetic sequence is easier to verify for purity/identity by HPLC than a tissue extract, which matters for research-grade sourcing.
• Regulatory footing. Several Cytomaxes are registered drugs in Russia (cortexin, retinalamin, thymalin); the Cytogens are generally sold as research compounds. None is FDA-approved.
• Evidence depth. The most human data sits with epithalon (Cytogen) and thymalin (Cytomax). The organ-specific tripeptides lean heavily on extrapolation from the class.

How They’re Used in Research

Across both classes, the vault notes describe the same “course” tradition rather than continuous daily use:

• Pulsed, cyclical dosing. Short, intensive courses — typically 10-20 days — repeated only 2-4 times per year (seasonally/quarterly). The bioregulation hypothesis holds that benefits persist after the course ends, so continuous year-round dosing is not the norm.
• Typical research amounts. Many of the organ peptides are described at 10-20 mg per cycle (crystagen, livagen, vesugen, svetinorm, glandokort, ventfort). thymalin is described at ~10 mg/day for 5-10 days, with low-dose maintenance options. epithalon research protocols use ~5-10 mg/day for 10-20 days, 2-3x/year.
• Oral vs. injectable. Cytogens skew oral/SubQ; Cytomaxes skew injectable. retinalamin is notable as a locally injected ocular peptide rather than a systemic one.
• Monitoring. The immune-targeting peptides (vilon, crystagen, thymalin) pair with CBC/CMP bloodwork; glandokort adds AM cortisol given its HPA-axis target. Exact reconstitution volumes are generally not specified in the source notes, and no standardized, peer-reviewed reconstitution or per-dose protocol exists for this line — instructions are vendor/manufacturer-specific (and vary by SKU), which is itself a reason to treat dosing figures here as research-use reference points rather than validated regimens.

Cytogen-Cytomax Pairing

A practical convention in the bioregulator tradition is to pair a Cytomax and a Cytogen that target the same organ — the idea being that the natural extract and the synthetic fragment reinforce the same tissue signal. The vault data supports several same-organ pairs:

• Thymus / immune: vilon (Cytogen) and crystagen (Cytogen) alongside thymalin (Cytomax). The vault explicitly notes vilon “complements thymalin in immune stacks,” making the thymus the best-documented pairing axis.
• Liver: livagen (Cytogen) and svetinorm (Cytomax) — the notes flag them as same-function liver peptides.
• Vascular: vesugen (Cytogen) and ventfort (Cytomax) — explicitly described as functional counterparts targeting vascular tissue.
• Pineal / longevity: epithalon (Cytogen) as the synthetic version of natural epithalamin (Cytomax).

A caution: the vault confirms the same-organ relationships above, and confirms the vilon + thymalin immune pairing as a stacking convention. There is one genuine human signal for additive combination — but it is between two Cytomax-type extracts, not a Cytogen+Cytomax pair: in Khavinson & Morozov’s 6-8-year cohort of 266 older adults (PMID 14523363), Thymalin plus Epithalamin together cut mortality ~2.5-fold versus controls, exceeding either agent alone (~2.0-2.1× Thymalin, ~1.6-1.8× Epithalamin), and a subgroup dosed with both annually for 6 years reached a 4.1-fold reduction. That is the strongest combination evidence in the family, and it is still Russian-language, non-randomized observational data. The broader claim that every Cytogen-Cytomax pair produces measurable additive synergy is not established by controlled data — no head-to-head trial of a synthetic Cytogen combined with its organ-extract Cytomax sibling was located.

Evidence Honestly Graded

Not every compound in this family is equally supported. Here is the honest split:

• Most human data — epithalon (Cytogen). 35+ years of study, including Khavinson’s multi-year elderly-cohort work reporting improved aging biomarkers, restored melatonin rhythms, and reduced mortality (the pineal extract epithalamin that epithalon reproduces cut mortality ~1.6-1.8-fold over 6-8 years; PMID 14523363), plus recent international validation of telomerase activation in human cell lines (PMID 40908429) and antioxidant wound-healing effects in a diabetic-retinopathy model (PMID 40493162). Still: no FDA-registered trial, predominantly Russian primary evidence, with longitudinal confounders.
• Most clinical track record — thymalin (Cytomax). Decades of Russian clinical use in elderly/immune patients with a strong reported safety record; in the same 266-patient cohort it reduced mortality ~2.0-2.1-fold (PMID 14523363), and its active KE/EW dipeptide fractions have been characterized at the gene-expression level (PMID 37686182). Mechanistic and clinical detail is real but, again, largely Russian-language and not FDA-grade.
• Registered Russian drugs with localized data — cortexin, retinalamin (Cytomaxes). Used clinically (neurology and ophthalmology respectively), which gives them a regulatory footing the synthetics lack — but Western RCT validation is limited.
• Largely extrapolated — vilon, crystagen, livagen, vesugen (Cytogens) and svetinorm, glandokort, ventfort (organ extracts). These ride on the class rationale and mechanistic plausibility far more than on their own dedicated human trials. The vault is explicit that this group has limited Western clinical data and that the core peptide-DNA mechanism is controversial.

Bottom line: treat the family as one with two genuinely well-studied anchors (epithalon and thymalin) and a long tail of organ-specific siblings whose individual human evidence is thin. The taxonomy is real and useful; the per-compound clinical proof is uneven.

Where to Buy

Because these compounds are sold for research purposes only and are not FDA-approved, sourcing quality and third-party testing matter more than price. With unapproved research peptides, a published Certificate of Analysis (COA) and HPLC purity/identity data are the most important quality signals — and they matter more for Cytomaxes than Cytogens, since a tissue-extract complex is harder to verify than a single defined synthetic sequence.

• For synthetic Cytogens (e.g., epithalon): VialBase’s recommended vendor is BioLongevity Labs, which provides research-grade material. Customer discount: 15% off with code VIALBASE.
• For the broader Khavinson line (e.g., crystagen): Certified-Pep is a US-based research-peptide vendor that carries Khavinson-family peptides, performs third-party HPLC testing, and publishes COAs on its product pages with cold-chain shipping.

When evaluating any vendor, prioritize third-party-tested products with published, lot-specific COAs, proper lyophilization, and cold-chain handling. Confirm the COA matches the lot you receive, and always comply with the laws and regulations applicable in your jurisdiction.

Affiliate disclosure: the vendor links above are affiliate links, and VialBase may earn a commission on qualifying purchases at no additional cost to you. This does not influence our research-based editorial coverage.

Frequently Asked Questions

What is the difference between a Cytogen and a Cytomax? A Cytogen is a short synthetic peptide (usually 2-4 amino acids) built to mimic an active peptide fragment, such as vilon or epithalon. A Cytomax is a natural polypeptide complex extracted from a young animal’s organ, such as thymalin or cortexin. Both target a specific organ; they differ in origin and composition.

Which one is better? Neither is universally “better” — they are two delivery formats for the same bioregulation idea. Cytogens offer a defined sequence and often oral dosing; Cytomaxes carry the full natural peptide mixture and have more clinical track record in Russia for a few members. The most human evidence sits with epithalon (Cytogen) and thymalin (Cytomax).

Are Khavinson bioregulators FDA-approved? No. None of these compounds is FDA-approved for human use; they are sold for research purposes only. A few Cytomaxes (cortexin, retinalamin, thymalin) are registered drugs in Russia, which is a different regulatory regime from the FDA.

Is the science behind them solid? Partly. The pulsed-course tradition and decades of regional use are real, and epithalon‘s telomerase activation has recent international support. But the core hypothesis — short peptides directly steering gene expression — is scientifically controversial, and most studies are Russian-language with designs below FDA-grade rigor. Treat it as a plausible, regionally-supported model, not proven biology.

Can you stack a Cytogen with a Cytomax? The tradition is to pair compounds that target the same organ — for example vilon (Cytogen) with thymalin (Cytomax) for the thymus, which the vault notes as a real stacking convention. Same-organ pairs exist for liver (livagen/svetinorm) and vascular (vesugen/ventfort) as well. Strong additive-synergy claims beyond documented stacking aren’t backed by controlled data.

How are they dosed in research? In short, pulsed courses rather than continuously — typically 10-20 days, repeated 2-4 times per year. Many organ peptides are described at 10-20 mg per cycle; thymalin at ~10 mg/day for 5-10 days; epithalon at ~5-10 mg/day for 10-20 days. This is research-use information, not a prescribed human protocol.

Are Cytogens oral and Cytomaxes injectable? As a rule of thumb, yes. Cytogens emphasize oral (or SubQ) availability, which is part of their appeal. Classic Cytomaxes like thymalin, cortexin, and retinalamin are injection-first in clinical practice (retinalamin is even injected locally around the eye). Some organ-extract bioregulators are also described with oral options.

Where does Epithalon fit — Cytogen or Cytomax? Chemically, epithalon is a Cytogen: a synthetic tetrapeptide built as the lab version of natural epithalamin (the pineal Cytomax). In practice it’s usually discussed on its own as the flagship longevity peptide rather than as one of the organ-specific bioregulator pairs.

References

• VialBase compound profile — Vilon (vault: Peptides/Compounds/Vilon.md)
• VialBase compound profile — Livagen (vault: Peptides/Compounds/Livagen.md)
• VialBase compound profile — Crystagen (vault: Peptides/Compounds/Crystagen.md)
• VialBase compound profile — Vesugen (vault: Peptides/Compounds/Vesugen.md)
• VialBase compound profile — Epithalon (vault: Peptides/Compounds/Epithalon.md)
• VialBase compound profile — Thymalin (vault: Peptides/Compounds/Thymalin.md)
• VialBase compound profile — Svetinorm (vault: Peptides/Compounds/Svetinorm.md)
• VialBase compound profile — Glandokort (vault: Peptides/Compounds/Glandokort.md)
• VialBase compound profile — Ventfort (vault: Peptides/Compounds/Ventfort.md)
• VialBase compound profile — Retinalamin (vault: Peptides/Compounds/Retinalamin.md)
• VialBase compound profile — Cortexin (vault: Peptides/Compounds/Cortexin.md)
• The Ultimate Peptides Bible (2026), Tom Ralston — cited source for the vault compound profiles above

Peer-reviewed Khavinson primary/taxonomy sources (predominantly Russian research group):

• PMID: 12374906 — Khavinson, Neuro Endocrinol Lett, 2002. The foundational monograph defining the design principle behind the two classes: organ-extract complexes (e.g., epithalamin, thymalin) and the shorter synthetic peptides built to reproduce them (dipeptides specific for the thymus, tetrapeptides for heart/liver/cortex/pineal, e.g., Ala-Glu-Asp-Gly = Epitalon); lays out the “peptide theory of ageing.”
• PMID: 14523363 — Khavinson et al., Neuro Endocrinol Lett, 2003. Controlled clinical cohort, 266 older adults over 6-8 years; Thymalin and Epithalamin (and their combination) reduced mortality vs. control. The single strongest human outcome in the class — but observational and Russian-language.
• PMID: 12577695 — Khavinson et al., Adv Gerontol, 2002. Russian-language geroprotective data underpinning the human-life-extension claim.
• PMID: 11163623 — Anisimov et al., Mech Ageing Dev, 2001. Animal evidence that the synthetic short peptides (Cytogen analogues) reproduce extract effects on lifespan/tumour incidence.
• PMID: 31808038 — Khavinson et al., Stem Cell Rev Rep, 2020. Modern mechanistic review of how ultrashort peptide bioregulators act on gene expression/differentiation.
• PMID: 37686182 — Linkova et al., Int J Mol Sci, 2023. Characterizes Thymalin’s active dipeptide fractions (KE = the Vilon sequence), bridging the Cytomax-extract and Cytogen-synthetic forms.

Epithalon-specific recent (international, peer-reviewed):

• PMID: 40908429 — Al-Dulaimi et al., Biogerontology, 2025. Verified real; in-vitro telomere-maintenance.
• PMID: 40493162 — Gatta et al., Stem Cell Rev Rep, 2025. Verified real; antioxidant tissue-repair.

Evidence gaps stated honestly:

• Svetinorm, Glandokort, and Ventfort have no PubMed-indexed literature of any kind (composition, pharmacology, or trials); everything known about them is vendor/manufacturer-reported.
• Controlled trials for the organ-specific bioregulators are predominantly Russian-language and non-randomized/observational (e.g., the Khavinson cohort above; Russian neurology trials of Cortexin such as PMID 18193579). Independent, FDA-grade Western RCT validation of the class remains limited-to-absent — claims throughout this page are hedged accordingly.

JSON-LD (for )

{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "MedicalWebPage",
      "@id": "https://vialbase.com/compare/cytogens-vs-cytomaxes",
      "name": "Cytogens vs Cytomaxes: The Two Khavinson Bioregulator Classes Explained",
      "headline": "Cytogens vs Cytomaxes: The Two Khavinson Bioregulator Classes Explained",
      "description": "Cytogens are short synthetic peptides; Cytomaxes are natural organ-extract polypeptide complexes. The two Khavinson bioregulator classes, compared.",
      "url": "https://vialbase.com/compare/cytogens-vs-cytomaxes",
      "inLanguage": "en",
      "datePublished": "2026-06-05",
      "dateModified": "2026-06-05",
      "publisher": {
        "@type": "Organization",
        "name": "VialBase",
        "url": "https://vialbase.com"
      },
      "about": [
        { "@type": "Thing", "name": "Khavinson peptide bioregulators" },
        { "@type": "Thing", "name": "Cytogen peptides" },
        { "@type": "Thing", "name": "Cytomax peptides" }
      ],
      "mentions": [
        { "@type": "Drug", "name": "Vilon" },
        { "@type": "Drug", "name": "Crystagen" },
        { "@type": "Drug", "name": "Livagen" },
        { "@type": "Drug", "name": "Vesugen" },
        { "@type": "Drug", "name": "Epithalon" },
        { "@type": "Drug", "name": "Thymalin" },
        { "@type": "Drug", "name": "Cortexin" },
        { "@type": "Drug", "name": "Retinalamin" },
        { "@type": "Drug", "name": "Svetinorm" },
        { "@type": "Drug", "name": "Glandokort" },
        { "@type": "Drug", "name": "Ventfort" }
      ],
      "isPartOf": {
        "@type": "WebSite",
        "name": "VialBase",
        "url": "https://vialbase.com"
      },
      "disclaimer": "Research-use and educational content only. Not medical advice. These compounds are not FDA-approved and are sold for research purposes only."
    },
    {
      "@type": "BreadcrumbList",
      "itemListElement": [
        { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://vialbase.com" },
        { "@type": "ListItem", "position": 2, "name": "Compare", "item": "https://vialbase.com/compare" },
        { "@type": "ListItem", "position": 3, "name": "Cytogens vs Cytomaxes", "item": "https://vialbase.com/compare/cytogens-vs-cytomaxes" }
      ]
    },
    {
      "@type": "FAQPage",
      "mainEntity": [
        {
          "@type": "Question",
          "name": "What is the difference between a Cytogen and a Cytomax?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "A Cytogen is a short synthetic peptide (usually 2-4 amino acids) built to mimic an active peptide fragment, such as Vilon or Epithalon. A Cytomax is a natural polypeptide complex extracted from a young animal's organ, such as Thymalin or Cortexin. Both target a specific organ; they differ in origin and composition."
          }
        },
        {
          "@type": "Question",
          "name": "Which one is better, Cytogens or Cytomaxes?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Neither is universally better — they are two delivery formats for the same bioregulation idea. Cytogens offer a defined sequence and often oral dosing; Cytomaxes carry the full natural peptide mixture and have more clinical track record in Russia. The most human evidence sits with Epithalon (Cytogen) and Thymalin (Cytomax)."
          }
        },
        {
          "@type": "Question",
          "name": "Are Khavinson bioregulators FDA-approved?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "No. None of these compounds is FDA-approved for human use; they are sold for research purposes only. A few Cytomaxes (Cortexin, Retinalamin, Thymalin) are registered drugs in Russia, which is a different regulatory regime from the FDA."
          }
        },
        {
          "@type": "Question",
          "name": "Is the science behind Khavinson bioregulators solid?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Partly. The pulsed-course tradition and decades of regional use are real, and Epithalon's telomerase activation has recent international support. But the core hypothesis that short peptides directly steer gene expression is scientifically controversial, and most studies are Russian-language with designs below FDA-grade rigor."
          }
        },
        {
          "@type": "Question",
          "name": "Can you stack a Cytogen with a Cytomax?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "The tradition is to pair compounds that target the same organ — for example Vilon (Cytogen) with Thymalin (Cytomax) for the thymus. Same-organ pairs exist for liver (Livagen/Svetinorm) and vascular (Vesugen/Ventfort). Strong additive-synergy claims beyond documented stacking aren't backed by controlled data."
          }
        },
        {
          "@type": "Question",
          "name": "How are Khavinson bioregulators dosed in research?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "In short, pulsed courses rather than continuously — typically 10-20 days, repeated 2-4 times per year. Many organ peptides are described at 10-20 mg per cycle; Thymalin at about 10 mg/day for 5-10 days; Epithalon at about 5-10 mg/day for 10-20 days. This is research-use information, not a prescribed human protocol."
          }
        },
        {
          "@type": "Question",
          "name": "Are Cytogens oral and Cytomaxes injectable?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "As a rule of thumb, yes. Cytogens emphasize oral or subcutaneous availability, which is part of their appeal. Classic Cytomaxes like Thymalin, Cortexin, and Retinalamin are injection-first in clinical practice; Retinalamin is even injected locally around the eye. Some organ-extract bioregulators are also described with oral options."
          }
        },
        {
          "@type": "Question",
          "name": "Where does Epithalon fit — Cytogen or Cytomax?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Chemically, Epithalon is a Cytogen: a synthetic tetrapeptide built as the lab version of natural epithalamin (the pineal Cytomax). In practice it is usually discussed on its own as the flagship longevity peptide rather than as one of the organ-specific bioregulator pairs."
          }
        }
      ]
    }
  ]
}